Koers Puma Biotechnology Inc Nyse
Aandelen
US74587V1070
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 231 mln. 216 mln. | Omzet 2025 * | 233 mln. 217 mln. | Marktkapitalisatie | 239 mln. 223 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 13 mln. 12,15 mln. | Nettowinst (verlies) 2025 * | 14 mln. 13,08 mln. | EV/omzet 2024 * | 1,04 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,03 x |
K/w-verhouding 2024 * |
19,2
x | K/w-verhouding 2025 * |
29,3
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 84,6% |
Recentste transcriptie over Puma Biotechnology Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Alan Auerbach
CEO | Chief Executive Officer | 54 | 15-09-10 |
Maximo Nougues
DFI | Director of Finance/CFO | 55 | 05-11-18 |
Alvin Wong
CTO | Chief Tech/Sci/R&D Officer | 71 | 01-03-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 23-02-18 |
Jay Moyes
BRD | Director/Board Member | 70 | 27-04-12 |
Alan Auerbach
CEO | Chief Executive Officer | 54 | 15-09-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,67% | 42,4 mld. | |
+46,73% | 40,04 mld. | |
-6,20% | 28,31 mld. | |
+6,55% | 24,94 mld. | |
-21,66% | 18,96 mld. | |
+29,96% | 12,3 mld. | |
-1,57% | 11,95 mld. | |
+16,03% | 11,32 mld. | |
-4,80% | 11,55 mld. |